Evidence map›Paper›PMID 32670419›Full record

ArticleTherapeutic advances in medical oncology2020

Use of patient derived orthotopic xenograft models for real-time therapy guidance in a pediatric sporadic malignant peripheral nerve sheath tumor.

Juana Fernández-Rodríguez, Andrés Morales La Madrid, Bernat Gel, Alicia Castañeda Heredia, Héctor Salvador, María Martínez-Iniesta, Catia Moutinho, Jordi Morata, Holger Heyn, Ignacio Blanco and 10 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Juana Fernández-RodríguezHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Andrés Morales La MadridPediatric Oncology Department, Hospital Sant Joan de Déu, Barcelona, Catalunya, Spain.
Bernat GelCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain.
Alicia Castañeda HerediaPediatric Oncology Department, Hospital Sant Joan de Déu, Barcelona, Catalunya, Spain.
Héctor SalvadorPediatric Oncology Department, Hospital Sant Joan de Déu, Barcelona, Catalunya, Spain.
María Martínez-IniestaProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Catia MoutinhoCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Catalunya, Spain.
Jordi MorataCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Catalunya, Spain.
Holger HeynCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Catalunya, Spain.
Ignacio BlancoPrograma d'Assessorament i Genètica Clínica, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
Edgar Creus-BachillerHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Gabriel CapellaHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Lourdes FarréProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
August VidalCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain.
Francisco SoldadoPediatric hand surgery and microsurgery, Hospital Sant Joan de Déu, Universitat de Barcelona, Spain.
Lucas KrauelPediatric Surgical Oncology, Pediatric Surgery Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Spain.
Mariona SuñolPathology Department, Hospital Sant Joan de Déu, Barcelona, Spain.
Eduard SerraCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain.
Alberto VillanuevaProcure Program, Catalan Institute of Oncology, Hospitalet de Llobregat (Barcelona) and CIBERONC, Av. Gran Via 199-203, Hospitalet de Llobregat, 08908, Spain.
Conxi LázaroHereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Av. Gran Via 199-203, Hospitalet de Llobregat, 08908, Spain.ORCID https://orcid.org/0000-0002-7198-5906
Hospital Sant Joan de Déu Barcelona · ESInstitut d'Investigació Biomédica de Bellvitge · ESCentre for Genomic Regulation · ESBellvitge University Hospital · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESHospital Universitari Germans Trias i Pujol · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to test the feasibility and utility of developing patient-derived orthotopic xenograft (PDOX) models for patients with malignant peripheral nerve sheath tumors (MPNSTs) to aid therapeutic interventions in real time. PATIENT &

methodsA sporadic relapsed MPNST developed in a 14-year-old boy was engrafted in mice, generating a PDOX model for use in co-clinical trials after informed consent. SNP-array and exome sequencing was performed on the relapsed tumor. Genomics, drug availability, and published literature guided PDOX treatments.

resultsA MPNST PDOX model was generated and expanded. Analysis of the patient's relapsed tumor revealed mutations in the

conclusionOur results indicate the feasibility of generating MPNST-PDOX and genomic characterization to guide treatment in real time. Although the treatment responses observed in our model did not fully recapitulate the patient's response, this pilot study identify key aspects to improve our co-clinical testing approach in real time.

Indexed as

exome sequencingMPNSTPDOX modelpersonalized medicineSNP-arraytargeted drug treatment

Identifiers

PMID32670419
PMCPMC7339074
OpenAlexW3040455749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.